Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775239209> ?p ?o ?g. }
- W2775239209 endingPage "984" @default.
- W2775239209 startingPage "979" @default.
- W2775239209 abstract "BackgroundThere is no standard first-line chemotherapy for recurrent/metastatic (RM) or unresectable locally advanced (LA) salivary gland carcinoma (SGC).Patients and methodsWe conducted a single institution, open-label, single arm, phase II trial of combined androgen blockade (CAB) for androgen receptor (AR)-positive SGC. Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks. Bicalutamide was administered orally at a daily dose of 80 mg. Patients were treated until progressive disease or unacceptable toxicities.ResultsThirty-six eligible patients were enrolled. Thirty-three patients had RM disease and three patients had LA disease. The pathological diagnoses were salivary duct carcinoma (34 patients, 94%) and adenocarcinoma, NOS (two patients, 6%). The best overall response rate was 41.7% [n = 15, 95% confidence interval (CI), 25.5%–59.2%], the clinical benefit rate was 75.0% (n = 27, 95% CI, 57.8%–87.9%). The median progression-free survival was 8.8 months (95% CI, 6.3–12.3 months) and the median overall survival was 30.5 months (95% CI, 16.8 months to not reached). Additional analyses between treatment outcomes and clinicopathological factors or biomarkers including AR positivity, human epidermal growth factor receptor 2 status, and its complex downstream signaling pathway gene mutations showed no statistically significant differences. Elevated grade 3 liver transaminases and increased serum creatinine were reported in two patients, respectively. Discontinuation of leuprorelin acetate or bicalutamide due to adverse event occurred in one patient.ConclusionThis study suggests that CAB has equivalent efficacy and less toxicity for patients with AR-positive RM or unresectable LA SGC compared with conventional chemotherapy, which warrants further study.Clinical Trial RegistrationUMIN-CTR (http://www.umin.ac.jp/ctr/index-j.htm), identification number: UMIN000005703" @default.
- W2775239209 created "2017-12-22" @default.
- W2775239209 creator A5001935081 @default.
- W2775239209 creator A5006683327 @default.
- W2775239209 creator A5008563527 @default.
- W2775239209 creator A5014779820 @default.
- W2775239209 creator A5020199498 @default.
- W2775239209 creator A5023589367 @default.
- W2775239209 creator A5028984479 @default.
- W2775239209 creator A5044023639 @default.
- W2775239209 creator A5050934937 @default.
- W2775239209 creator A5068533812 @default.
- W2775239209 creator A5076710089 @default.
- W2775239209 creator A5077292737 @default.
- W2775239209 creator A5079988634 @default.
- W2775239209 date "2018-04-01" @default.
- W2775239209 modified "2023-10-17" @default.
- W2775239209 title "A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma" @default.
- W2775239209 cites W1548322682 @default.
- W2775239209 cites W1560364460 @default.
- W2775239209 cites W2049325430 @default.
- W2775239209 cites W2070045894 @default.
- W2775239209 cites W2083354031 @default.
- W2775239209 cites W2088005396 @default.
- W2775239209 cites W2107283511 @default.
- W2775239209 cites W2117460748 @default.
- W2775239209 cites W2127210104 @default.
- W2775239209 cites W2128512366 @default.
- W2775239209 cites W2131902113 @default.
- W2775239209 cites W2137853125 @default.
- W2775239209 cites W2143398431 @default.
- W2775239209 cites W2146442501 @default.
- W2775239209 cites W2155961584 @default.
- W2775239209 cites W2158039963 @default.
- W2775239209 cites W2293008070 @default.
- W2775239209 cites W2323691395 @default.
- W2775239209 cites W2325489602 @default.
- W2775239209 cites W2336391717 @default.
- W2775239209 cites W2342227699 @default.
- W2775239209 cites W2464502417 @default.
- W2775239209 cites W2577862693 @default.
- W2775239209 cites W2739541956 @default.
- W2775239209 cites W2999517068 @default.
- W2775239209 doi "https://doi.org/10.1093/annonc/mdx771" @default.
- W2775239209 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5913639" @default.
- W2775239209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29211833" @default.
- W2775239209 hasPublicationYear "2018" @default.
- W2775239209 type Work @default.
- W2775239209 sameAs 2775239209 @default.
- W2775239209 citedByCount "129" @default.
- W2775239209 countsByYear W27752392092018 @default.
- W2775239209 countsByYear W27752392092019 @default.
- W2775239209 countsByYear W27752392092020 @default.
- W2775239209 countsByYear W27752392092021 @default.
- W2775239209 countsByYear W27752392092022 @default.
- W2775239209 countsByYear W27752392092023 @default.
- W2775239209 crossrefType "journal-article" @default.
- W2775239209 hasAuthorship W2775239209A5001935081 @default.
- W2775239209 hasAuthorship W2775239209A5006683327 @default.
- W2775239209 hasAuthorship W2775239209A5008563527 @default.
- W2775239209 hasAuthorship W2775239209A5014779820 @default.
- W2775239209 hasAuthorship W2775239209A5020199498 @default.
- W2775239209 hasAuthorship W2775239209A5023589367 @default.
- W2775239209 hasAuthorship W2775239209A5028984479 @default.
- W2775239209 hasAuthorship W2775239209A5044023639 @default.
- W2775239209 hasAuthorship W2775239209A5050934937 @default.
- W2775239209 hasAuthorship W2775239209A5068533812 @default.
- W2775239209 hasAuthorship W2775239209A5076710089 @default.
- W2775239209 hasAuthorship W2775239209A5077292737 @default.
- W2775239209 hasAuthorship W2775239209A5079988634 @default.
- W2775239209 hasBestOaLocation W27752392091 @default.
- W2775239209 hasConcept C121608353 @default.
- W2775239209 hasConcept C126322002 @default.
- W2775239209 hasConcept C126894567 @default.
- W2775239209 hasConcept C143998085 @default.
- W2775239209 hasConcept C197934379 @default.
- W2775239209 hasConcept C2776694085 @default.
- W2775239209 hasConcept C2778575703 @default.
- W2775239209 hasConcept C2778822529 @default.
- W2775239209 hasConcept C2778894405 @default.
- W2775239209 hasConcept C2779093440 @default.
- W2775239209 hasConcept C2779322244 @default.
- W2775239209 hasConcept C2780192828 @default.
- W2775239209 hasConcept C2780962315 @default.
- W2775239209 hasConcept C61367390 @default.
- W2775239209 hasConcept C71315377 @default.
- W2775239209 hasConcept C71924100 @default.
- W2775239209 hasConcept C90924648 @default.
- W2775239209 hasConceptScore W2775239209C121608353 @default.
- W2775239209 hasConceptScore W2775239209C126322002 @default.
- W2775239209 hasConceptScore W2775239209C126894567 @default.
- W2775239209 hasConceptScore W2775239209C143998085 @default.
- W2775239209 hasConceptScore W2775239209C197934379 @default.
- W2775239209 hasConceptScore W2775239209C2776694085 @default.
- W2775239209 hasConceptScore W2775239209C2778575703 @default.
- W2775239209 hasConceptScore W2775239209C2778822529 @default.
- W2775239209 hasConceptScore W2775239209C2778894405 @default.
- W2775239209 hasConceptScore W2775239209C2779093440 @default.